Hematology Analyzers and Reagents Market is expected to reach US$ 13,007.87 million by 2027

Hematology Analyzers & Reagents Market: Key Insights

According to our latest study on “Hematology Analyzers & Reagents Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Product and Service, Application, End User, and Geography,” the market is expected to reach US$ 13,007.87 million by 2027 from US$ 7,252.54 million in 2019; it is expected to grow at a CAGR of 7.6% from 2020 to 2027. The hematology analyzers & reagents market growth is attributed to the increasing incidence of hematologic diseases and technological advancements in hematology analyzers. These drivers are expected to have significant short- and mid-term impacts. However, the steep prices of high-tier systems are expected to hamper the growth of the hematology analyzers & reagents market.

Hematology analyzers and reagents are used in the diagnosis and treatment of a wide range of diseases related to red blood cells, white blood cells, platelets, blood vessels, bone marrow, lymph nodes, spleen, and the proteins involved in bleeding and clotting. The major techniques used by a hematology analyzer may be flow cytometry, spectrophotometry, electrical impedance, and digital microscopy with artificial intelligence capabilities. Hematology reagents help in the qualitative and quantitative analysis of the morphology of the blood, its components, and blood-forming tissues. The hematology reagents include slide stains, hematology analyzer reagents, hemoglobin testing reagents, microscopy testing reagents, among others. These can be diluents, lysing reagents, probe cleaners, and others.

The primary products and services in the hematology analyzers & reagents market are hematology products and services, hemostasis products and services, immunohematology products and services. The hematology products and services are expected to hold the major share of the hematology analyzers & reagent market size, which is expected to increase during the forecast period. The segment is expected to hold almost half of the hematology analyzers & reagents market and witness growth at the highest CAGR among the product and service segment of the hematology analyzers & reagents market.

The impact of blood diseases is not necessarily limited to any one part of the human body. A few of the common blood diseases include anemia; hemophilia; von Willebrand disease (VWD); and blood cancers such as myeloma, leukemia, and lymphoma. Several blood diseases are hereditary, and the rising prevalence of these diseases boosts demands for blood transfusion, which is further escalating the demand for hematology analyzers and reagents.

Anemia is a common blood disorder, and according to the National Heart, Lung, and Blood Institute, it affects more than 3 million Americans every year. Moreover, according to the World Health Organization (WHO), the disorder affected ~1.62 billion people worldwide in 2018. Anemia is also prevalent in the Indian population and affects the quality of life of a remarkable number of people. According to the National Family Health Survey (NFHS) conducted in India in 2018, anemia affected ~58.6% of children and 50.4% of pregnant women in the country in 2016. Further, according to the Centers for Disease Control and Prevention (CDC), hemophilia A affects ~1 in 5,000 male births in the US on an average each year. A CDC survey for 2017 reported that VWD, one of the most common bleeding disorders, affects up to 1% of the general population. During 2012–2016, more than 14,600 men, women, and children were seen at hemophilia treatment centers for the treatment of VWD. The increasing incidence of blood-related diseases is augmenting the growth of the hematology analyzers and reagents market.

Also, the technological advancements in the hematology analyzers are driving the demand for hematology analyzers and reagents for various applications. For instance, in May 2020, Beckman Coulter introduced DxH 690T hematology analyzer in the US to streamline workflow as well as minimize the downtime in medium-sized laboratories. Also, the company released the DxH 560 AL Hematology Analyzer (with Reagents) for mid-sized laboratories which is the ideal instrument to use with difficult-to-draw patients (infants, oncology, and elderly) as it only needs a 17 microliters sample – less than a drop of blood, one of the smallest aspiration volumes on the market. Additionally, the DxH 560 AL uses ~30% less counter space than other analyzers in its class. These new product launches signify an improvement in technology of hematology analyzers and is expected to drive the demand for these analyzers and its reagents in the coming years driving the hematology analyzers & reagents market growth.

Hematology Analyzers & Reagents Market: Competition Landscape and Key Developments

Clinical Diagnostic Solutions, Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Danaher; Bio-Rad Laboratories Inc.; Abbott; Diatron; ERBA Diagnostics Inc.; EKF Diagnostics; HORIBA Medical; and Biosystems SA are among the key companies operating in the hematology analyzers & reagents market. The companies adopt product innovation strategies to meet the evolving customer demands worldwide, which also permits them to maintain their brand name in the global hematology analyzers & reagents market. Also, market players create partnerships, collaborations, and contracts with hospitals, diagnostic centers, and academic & research institutes to provide hematology analyzers & reagents for various studies, which is driving the hematology analyzers & reagents market growth.

Some of the recent developments in the hematology analyzers & reagents market include:

In May 2019, Horiba Medical and Laboratorio Echevarne, one of the major laboratory medicine providers in Europe, signed a multi-year, multi-site contract for the supply of the high range fully automated Hematology analyzers during the EuroMedLab Congress

In February 2019, EKF Diagnostics announced that it had signed a private label distribution agreement with McKesson Medical-Surgical Inc. for the company’s hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.